Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A simple blood test may catch hidden heart failure before It's too late

NCT ID NCT07731490

Prevention Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

Heart failure often goes undiagnosed because its early symptoms—like fatigue and shortness of breath—are mistaken for normal aging. This study tests whether a three-part strategy can change that: raising awareness among patients and doctors, using a blood test (NT-proBNP) to spot heart failure early in high-risk older adults, and starting guideline-recommended treatment right away. Researchers will track whether this approach reduces hospitalizations for acute heart failure over 18 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a strategy combining increased awareness, NT-proBNP blood testing, and guideline-directed heart failure treatment
What this could lead to
If successful, this approach could become a standard way to catch heart failure early and prevent hospitalizations in older adults.
What could go wrong
The trial is large but observational, so it cannot prove cause and effect. The strategy may not reduce hospitalizations as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 18,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Apr 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * General consent (GC) has not been rejected. * Age ≥ 65 years. * Elective percutaneous coronary intervention\* (PCI), pulmonary vein isolation\* (PVI), pacemaker implantation\* (PM, no cardiac resynchronisation), transcatheter aortic valve intervention\* (TAVI), major non-cardiac surgery\* or presenting with tachyarrhythmia to the emergency department (ED) (without a diagnosis of HF within 24h). * Exclusion criteria are assessed on day 1 after the procedure Exclusion Criteria: * Systolic blood pressure ≤ 95 mmHg * Estimated glomerular filtration rate (GFR) \<30 mL/min/1.73 m2. * Dementia documented in the medical history. * Metastatic cancer in the medical history. * Previously enrolled in this study. * Known HF. * Known allergies, hypersensitivity, or intolerance to SGLT2 Inhibitors / Loop Diuretics / MRA or is excipients. * Non-resident in the country of the recruiting site * Incapacity of the patient to make judgements * Patients not hospitalized overnight * Patients requiring intensive care unit (ICU) or intermediate care (IMC) stay beyond 11:00 a.m. on the first postoperative day or any post-interventional stroke unit stay until 8:00 a.m. on the first postoperative day. * Patients died prior to postinterventional day 1 (8:00 a.m.) * Severe aortic or mitral stenosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure (HF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure (HF)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    21 sites in 9 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cantonal Hospital Baden

    NOT_YET_RECRUITING

    Baden, 5404, Switzerland

  • Erasmus MC Rotterdam

    NOT_YET_RECRUITING

    Rotterdam, 3015, Netherlands

  • Herzzentrum Leipzig, Klinik für Innere Medizin/Kardiologie

    NOT_YET_RECRUITING

    Leipzig, 04289, Germany

  • Hospital Istituto Cardiocentro Ticino

    NOT_YET_RECRUITING

    Lugano, 6900, Switzerland

  • KSA Kantonsspital Aarau

    NOT_YET_RECRUITING

    Aarau, 5001, Switzerland

  • Kantonsspital Luzern

    NOT_YET_RECRUITING

    Lucerne, 6000, Switzerland

  • Kantonsspital St. Gallen

    NOT_YET_RECRUITING

    Sankt Gallen, 9007, Switzerland

  • Konkuk University Medical Center

    RECRUITING

    Seoul, South Korea

  • Queen Giovanna University Hospital

    NOT_YET_RECRUITING

    Sofia, 1527, Bulgaria

  • Royal Infirmary Edinburgh

    NOT_YET_RECRUITING

    Edinburgh, EH16 4SB, United Kingdom

  • St. Claraspital AG

    NOT_YET_RECRUITING

    Basel, 4058, Switzerland

  • Stadtspital Zürich

    NOT_YET_RECRUITING

    Zurich, 8063, Switzerland

  • University Hospital Basel

    RECRUITING

    Basel, Basel, 4031, Switzerland

  • University Hospital Freiburg-Bad Krozingen

    NOT_YET_RECRUITING

    Freiburg im Breisgau, 79106, Germany

  • University Hospital Genève

    NOT_YET_RECRUITING

    Geneva, 1205, Switzerland

  • University Hospital Lausanne

    NOT_YET_RECRUITING

    Lausanne, Lausanne, 1005, Switzerland

  • University Hospital Pisa

    NOT_YET_RECRUITING

    Pisa, 56126, Italy

  • University Hospital Ramón y Cajal Madrid

    NOT_YET_RECRUITING

    Madrid, 28034, Spain

  • University Hospital Zurich

    NOT_YET_RECRUITING

    Zurich, 8091, Switzerland

  • Universitätsklinik für Innere Medizin II

    NOT_YET_RECRUITING

    Vienna, 1090, Austria

  • Universitätsklinikum der Ruhr-Universität Bochum

    NOT_YET_RECRUITING

    Herne, 44625, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.